An investigational immunotherapy drug helped people with uveal melanoma, an aggressive cancer of the eye, live longer than those who received current treatments for the disease, according to the results of a large clinical trial.
In a large clinical trial, cancer survivors treated with acupuncture had modest improvements in chronic pain compared with those who received standard pain treatments. The study, which did not include a placebo version of acupuncture, could not rule out a placebo effect for the improvement.
A clinical trial led by NCI physician-scientists found that children, teens, and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) who received a stem cell transplant after CD19-targeting CAR T-cell therapy lived longer than those treated with CAR T-cell therapy alone.
The Food and Drug Administration has approved idecabtagene vicleucel (Abecma) for some people with multiple myeloma. The approval is based, in part, on a small clinical study in which idecabtagene vicleucel partially or completely shrank tumors in 72% of patients.
The results of two trials suggest blinatumomab (Blincyto) may be a new standard treatment for children and young adults with high-risk relapsed B-ALL after remission has been achieved and before a stem cell transplant.
An international phase 3 clinical trial compared the combination of nivolumab and cabozantinib against sunitinib alone in people with advanced, untreated renal cell carcinoma. Researchers found that the combination therapy was significantly more effective at prolonging life without the cancer progressing.
Clinical Trials Information for Patients and Caregivers
Experts review clinical trial protocols before studies are launched to make sure that they are based on sound science. All clinical trials that are funded by the federal government must go through this type of review.
Most clinical trials run as planned from beginning to end. But sometimes trials are stopped early. This page discusses some of the reasons why clinical trials end early.
This phase 3 trial studies how well axillary reverse mapping works in preventing the swelling of lymph nodes (lymphedema) in people with breast cancer undergoing axillary lymph node dissection. Axillary reverse mapping may help to preserve the lymph node drainage system around the breast to prevent lymphedema after surgery.
This phase 1 trial will test a mesothelin-targeted immunotoxin, LMB-100, and the targeted drug tofacitinib (Xeljanz) for patients with previously treated pancreatic cancer, cholangiocarcinoma, or other solid tumors that express the protein mesothelin. Doctors will assess the safety and tolerability of the regimen, as well as determine if giving patients tofacitinib delays the formation of antibodies that block the effect of LMB-100.
This phase 3 trial will test how well chemotherapy and radiation therapy work with or without the immunotherapy drug atezolizumab (Tecentriq) for treating patients with localized muscle-invasive bladder cancer. Doctors want to see if adding atezolizumab to chemoradiotherapy improves the bladder preservation, overall survival, and duration of complete responses.
